Article
Oncology
Arif Manji, Yvan Samson, Rebecca J. Deyell, Donna L. Johnston, Victor A. Lewis, Alexandra P. Zorzi, Jason N. Berman, Kathy Brodeur-Robb, Ellen Morrison, Lynn Kee, Sushil Kumar, Sylvain Baruchel, James A. Whitlock, Daniel A. Morgenstern
Summary: Low-dose continuous oral chemotherapy combined with targeted tyrosine kinase inhibitors may be effective in inhibiting angiogenesis in children with relapsed or refractory solid tumors. A phase I study on the combination of oral topotecan and pazopanib showed good tolerability and few side effects, with stable disease achieved in 40% of patients. This combination may have a role in the maintenance setting following alternative chemotherapy regimens.
Article
Oncology
Vikas Garg, Lalit Kumar
Summary: Translational research and targeted therapies have significantly impacted the treatment of epithelial ovarian cancer. Recurrent ovarian cancer remains a challenge and requires innovative strategies. Metronomic chemotherapy, which inhibits angiogenesis and activates the immune system, has emerged as a promising approach.
Article
Chemistry, Multidisciplinary
Melgious Jin Yan Ang, Jeehyun Yoon, Mingzhu Zhou, Han-Lin Wei, Yi Yiing Goh, Zhenglin Li, Jia Feng, Haifang Wang, Qianqian Su, Derrick Sek Tong Ong, Xiaogang Liu
Summary: Nanoparticles modified with ligands can cross the blood-brain barrier, endocytose into the lysosomes of glioblastoma cells, and undergo endolysosomal escape under photochemical ionization. Metronomic chemotherapy using dual-drug-loaded nanocarriers can induce an enhanced antitumor effect 3.5 times greater than standard chemotherapy.
ADVANCED MATERIALS
(2022)
Review
Medicine, General & Internal
Piotr J. Wysocki, Maciej T. Lubas, Malgorzata L. Wysocka
Summary: This study investigated the actual effectiveness of metronomic chemotherapy in mCRPC patients who had failed all available standard therapies, and identified the optimal metronomic regimen for heavily pretreated mCRPC patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Hiroshi Kikuchi, Nako Maishi, Li Yu, Zi Jia, Cong Li, Masumi Sato, Ryo Takeda, Keita Ishizuka, Yasuhiro Hida, Nobuo Shinohara, Kyoko Hida
Summary: This study found that LDM CDDP combined with MTD GEM can more effectively inhibit tumor growth and bone metastasis compared to MTD CDDP. LDM CDDP reduces the accumulation of myeloid-derived suppressor cells, while MTD CDDP induces an inflammatory response in the tumor microenvironment.
BRITISH JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Han Wang, Huiying Sun, Bilin Liang, Fang Zhang, Fan Yang, Bowen Cui, Lixia Ding, Xiang Wang, Ronghua Wang, Jiaoyang Cai, Yanjing Tang, Jianan Rao, Wenting Hu, Shuang Zhao, Wenyan Wu, Xiaoxiao Chen, Kefei Wu, Junchen Lai, Yangyang Xie, Benshang Li, Jingyan Tang, Shuhong Shen, Yu Liu
Summary: This study characterizes the chromatin accessibility landscape in pediatric relapsed B-ALL and identifies subtype and drug response specific patterns.
NATURE COMMUNICATIONS
(2023)
Review
Medicine, General & Internal
Marta Banchi, Elisabetta Fini, Stefania Crucitta, Guido Bocci
Summary: Metronomic chemotherapy is a form of chemotherapy that maintains low but effective concentrations of drugs by regular administration, with the advantages of low toxicity, oral administration, and home-based treatment. It improves the quality of life for pediatric cancer patients and their caregivers and may also reduce the economic burden of pediatric anticancer therapy.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Minsik Park, Joohwan Kim, Taesam Kim, Suji Kim, Wonjin Park, Kwon-Soo Ha, Sung Hwan Cho, Moo-Ho Won, Jeong-Hyung Lee, Young-Guen Kwon, Young-Myeong Kim
Summary: The study revealed that low-dose doxorubicin can inhibit tumor growth and metastasis by inducing REDD1 expression to impair the function of tumor-associated endothelial cells. REDD1 was found to suppress the transcription of vascular endothelial growth factor receptor by inhibiting mTORC1-dependent translation, thus inhibiting tumor angiogenesis and lymphangiogenesis.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2021)
Review
Oncology
Marina Elena Cazzaniga, Nicoletta Cordani, Serena Capici, Viola Cogliati, Francesca Riva, Maria Grazia Cerrito
Summary: This article reviews the current state and underlying mechanisms of metronomic chemotherapy use, discussing new regimens, cancer types suitable for mCHT, and ongoing trials. It highlights that mCHT not only directly affects tumor cells, but also influences the cell microenvironment, making it a promising multi-target therapy.
Review
Medicine, General & Internal
Benjamin Carcamo, Giulio Francia
Summary: This study presents a retrospective case series of six Hispanic children with tumors who were treated with metronomic chemotherapy. The results show that the patients responded to metronomic therapy with only minor hematologic toxicity.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Camille Winnicki, Pierre Leblond, Franck Bourdeaut, Anne Pagnier, Gilles Paluenzela, Pascal Chastagner, Gwenaelle Duhil-De Benaze, Victoria Min, Helene Sudour-Bonnange, Catherine Piette, Natacha Entz-Werle, Sylvie Chabaud, Nicolas Andre
Summary: This study retrospectively analyzed pediatric patients with relapsed high-risk brain tumors treated with the METMAT or METMAT-like regimen. It found that this treatment approach can lead to sustained control of the tumors, with the best outcomes observed at first relapse.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Engineering, Biomedical
Ruby Maharjan, Jeong Uk Choi, Seho Kweon, Rudra Pangeni, Na Kyeong Lee, Seong Jin Park, Kwan-Young Chang, Jin Woo Park, Youngro Byun
Summary: In this study, a novel metronomic chemotherapy (MCT) featuring combined oral oxaliplatin (OXA) and pemetrexed (PMX) was investigated for its immune-modulating effects on colon cancer. The results showed that MCT improved tumor antigen presentation, increased functional T cells, and elicited tumor-specific long-term immune memory. When combined with anti-PD-1 therapy, MCT achieved a high rate of complete response and induced a tumor-specific memory response. This study highlights the importance of MCT in activating both innate and adaptive immune cells for the successful treatment of colon cancer.
Review
Oncology
Raquel Munoz, Alessandra Girotti, Denise Hileeto, Francisco Javier Arias
Summary: Metronomic chemotherapy with its multimodal effects shows promising inhibitory effects on primary tumors and metastases while supporting the potential use of nano-therapeutic agents. Understanding the complexity of cellular interactions in the tumor microenvironment could lead to long-lasting therapeutic actions.
Article
Chemistry, Multidisciplinary
Yuxue Xu, Feixue Ni, Daxi Sun, Yue Peng, Yaxuan Zhao, Xiaojun Wu, Shasha Li, Xiangyu Qi, Xinkang He, Min Li, Yizi Zhou, Chao Zhang, Miao Yan, Cuifang Yao, Shuaishuai Zhu, Yang Yang, Baijiao An, Chunhua Yang, Guilong Zhang, Wenguo Jiang, Jia Mi, Xinju Chen, Pengfei Wei, Geng Tian, Yin Zhang
Summary: This study reveals a novel role of glucagon in anti-cancer therapy by inhibiting angiogenesis and vascular mimicry, which enhances chemotherapy efficacy.
Article
Oncology
Chenfei Zhou, Chengfang Shangguan, Min Shi, Wenqi Xi, Junwei Wu, Hui Yang, Liting Guo, Qu Cai, Yan Shi, Jing Liu, Jun Zhang
Summary: This study aims to evaluate the safety and efficacy of the combination of PD-1 inhibitor camrelizumab and oral chemotherapy drug capecitabine (with metronomic dose) in patients with metastatic treatment-refractory solid tumors. The study is an open-label, single-center, multi-cohort phase Ib trial, with a planned enrollment of 20 subjects for each cohort. The total duration of the trial is expected to be 2 years.
Article
Gastroenterology & Hepatology
Beatrix Bencsikova, Zbynek Bortlicek, Jana Halamkova, Lenka Ostrizkova, Igor Kiss, Bohuslav Melichar, Tomas Pavlik, Ladislav Dusek, Dalibor Valik, Rostislav Vyzula, Lenka Zdrazilova-Dubska
BMC GASTROENTEROLOGY
(2015)
Article
Oncology
Mona A. Karlsen, Estrid V. S. Hogdall, Ib J. Christensen, Christer Borgfeldt, Grigorios Kalapotharakos, Lenka Zdrazilova-Dubska, Josef Chovanec, Christianne A. R. Lok, Anna Stiekema, Irene Mutz-Dehbalaie, Adam N. Rosenthal, Elizabeth K. Moore, Beth A. Schodin, Walfrido W. Sumpaico, Karin Sundfeldt, Bjorg Kristjansdottir, Ignacio Zapardiel, Claus K. Hogdall
GYNECOLOGIC ONCOLOGY
(2015)
Review
Biotechnology & Applied Microbiology
Michal Rihacek, Julie Bienertova-Vasku, Dalibor Valik, Jaroslav Sterba, Katerina Pilatova, Lenka Zdrazilova-Dubska
BIOMED RESEARCH INTERNATIONAL
(2015)
Article
Infectious Diseases
Eva Hajduskova, Ivan Literak, Ivo Papousek, Francisco B. Costa, Marketa Novakova, Marcelo B. Labruna, Lenka Zdrazilova-Dubska
TICKS AND TICK-BORNE DISEASES
(2016)
Article
Oncology
Josef Chovanec, Iveta Selingerova, Kristina Greplova, Sofie Leisby Antonsen, Monika Nalezinska, Claus Hogdall, Estrid Hogdall, Erik Sogaard-Andersen, Kirsten M. Jochumsen, Pavel Fabian, Dalibor Valik, Lenka Zdrazilova-Dubska
Review
Oncology
Katerina Pilatova, Beatrix Bencsikova, Regina Demlova, Dalibor Valik, Lenka Zdrazilova-Dubska
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2018)
Review
Oncology
Regina Demlova, Lenka Zdrazilova-Dubska, Jaroslav Sterba, Giorgio Stanta, Dalibor Valik
Review
Oncology
Katerina Pilatova, Kristina Greplova, Regina Demlova, Beatrix Bencsikova, Giannoula Lakka Klement, Lenka Zdrazilova-Dubska
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2013)
Article
Oncology
Regina Demlova, Martina Mrkvicova, Jaroslav Sterba, Hana Bernatikova, Jan Stary, Martina Sukova, Alena Mikuskova, Alica Chocholova, Beata Mladosievicova, Andrea Soltysova, Darina Behulova, Katerina Pilatova, Lenka Zdrazilova-Dubska, Dalibor Valik
Article
Parasitology
Pavel Siroky, Tomas Belohlavek, Ivo Papousek, David Jandzik, Peter Mikulicek, Michaela Kubelova, Lenka Zdrazilova-Dubska
PARASITES & VECTORS
(2014)
Article
Infectious Diseases
Lenka Dubska, Ivan Literak, Pavel Kverek, Eva Roubalova, Elena Kocianova, Veronika Taragelova
TICKS AND TICK-BORNE DISEASES
(2012)
Article
Oncology
Barbora Zwinsova, Vyacheslav A. Petrov, Martina Hrivnakova, Stanislav Smatana, Lenka Micenkova, Natalie Kazdova, Vlad Popovici, Roman Hrstka, Roman Sefr, Beatrix Bencsikova, Lenka Zdrazilova-Dubska, Veronika Brychtova, Rudolf Nenutil, Petra Videnska, Eva Budinska
Summary: This study suggests that dysbiosis of the gut microbiome plays a role in the heterogeneity of colorectal cancer, affecting its phenotypic, prognostic, and treatment response aspects. The dominance of oral pathogenic bacteria in tumour mucosa of CRC patients was observed, while changes in stool microbiome were associated with clinical parameters such as lymph node involvement and synchronous metastases. The study identified new associations between microorganisms and CRC, providing insights for potential new treatments and biomarkers.
Review
Physiology
R. Demlova, D. Valik, R. Obermannova, L. Zdrazilova-Dubska
PHYSIOLOGICAL RESEARCH
(2016)
Article
Oncology
R. Obermannova, L. Dusek, K. Greplova, J. Jarkovsky, J. Sterba, R. Vyzula, R. Demlova, L. Zdrazilova-Dubska, D. Valik
Article
Immunology
M. Hamanova, Zdrazilova L. Dubska, D. Valik, J. Lokaj
EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE
(2014)